HIV Accelerated Liver Disease in Uganda

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

786 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-12-20

Study Completion Date

2019-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- Liver disease is a leading cause of death in people who have the human immunodeficiency virus (HIV). It especially affects those who have both HIV and hepatitis B or C viruses. Most research on HIV-related liver disease has been conducted in North America and Europe. However, HIV-related liver disease in Uganda and other African nations may involve other diseases that are not common in the West, and may not involve hepatitis B or C. Researchers want to study HIV-related liver disease in Uganda to learn more about the differences between Western and African trends of this disease.

Objectives:

\- To study HIV-related liver disease in rural Uganda.

Eligibility:

* Individuals at least 18 years of age who were tested for possible liver disease. Some participants will have HIV infection; others will be uninfected.
* All participants will be from rural areas of Uganda.

Design:

* Participants will have at least two study visits.
* Participants will have a physical exam and medical history. They will complete a questionnaire about health and quality of life. Blood, urine, and stool samples will be collected. Participants will also have a liver scan to check for liver scarring, and an ultrasound to take images of the liver.
* Participants who may have liver disease will visit a local hospital for more tests. A liver biopsy will be performed to collect liver tissue samples.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatitis B and HIV Co-Infection in Patients in Uganda

NCT00782158

Hepatitis B HIV Infections

COMPLETED

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

NCT00326482

Liver Fibrosis Steatohepatitis Elevated Transaminases

COMPLETED

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

NCT04795219

NAFLD NAFLD-HIV Hiv

RECRUITING

Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa

NCT02060162

Hepatitis B Virus HIV Antiretroviral Therapy +3 more

COMPLETED

Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans

NCT02154035

HIV

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With improved survival following the introduction of highly active antiretroviral therapy (HAART), liver disease has become a leading cause of death among HIV-infected persons in Western cohorts, primarily affecting those co-infected with hepatitis B or C viruses (HBV, HCV). However, data are sparse on liver disease in HIV-infected populations from Uganda and other African nations, where the etiologies of liver disease are broader and include aflatoxin, schistosomiasis and other infectious and environmental agents. Our previous noninvasive study in rural, Rakai, Uganda indicates that the prevalence of significant liver fibrosis is high among HIV-infected individuals (17%) and is 50% higher than in HIV-uninfected persons, although the prevalence of viral hepatitis B co-infection is low (5%). The study presented here is a biopsy-based study that follows up on these results with the objectives of defining the etiology of liver disease and describing the mechanisms of HIV-accelerated liver fibrosis in this setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rakai Community Cohort

HIV Patients

No interventions assigned to this group

Rakai HIV Care Program

HIV Patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults aged 18 and older
2. Persons who are able and willing to provide informed consent
3. Persons who have a transient elastography score \>=9.0 kPa or have other evidence of liver disease, and who are willing to undergo an ultrasound and liver biopsy

i) Other evidence of liver disease: Persons with an LSM \<9.0 kPa who demonstrate liver transaminases at least 2-times greater than the upper limit of normal; those with persistently abnormal liver

transaminases over a period of three months during the year preceding enrollment; those who show abnormalities on their ultrasound; those with other laboratory tests indicating the possibility of liver disease; and/or those who have a clinical or medical indication for a liver biopsy.
4. Persons who are willing to have tissue samples undergo genetic testing
5. Persons who agree to have samples stored for the purpose of future research

Exclusion Criteria

1. Women who are pregnant
2. Persons with a cardiac device (i.e., pacemaker)
3. Participants who are not able to follow study instructions
4. Safety laboratory data indicating possible excess risk of bleeding including platelets \<75,000 and an INR\>=1.5. These safety laboratory values will be ascertained by obtaining a Complete Blood Count (CBC) and a Prothrombin Time (PT).
5. Evidence of decompensated liver disease including ascites, or hepatic encephalopathy
6. Persons who have any condition deemed, by the investigators, to be a contraindication to study participation

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes